1323140-64-2

Usage

Uses

Used in Pharmaceutical Industry:
(Z)-N-(1-chloro-1-(4-methoxyphenyl)-3-oxo-3-(piperidin-1-yl)prop-1-en-2-yl)benzamide is used as a potential pharmaceutical agent for its possible wide range of pharmacological effects due to the presence of the piperidine ring and other functional groups. (Z)-N-(1-chloro-1-(4-methoxyphenyl)-3-oxo-3-(piperidin-1-yl)prop-1-en-2-yl)benzamide's structural features make it a candidate for the development of new drugs targeting various medical conditions.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, (Z)-N-(1-chloro-1-(4-methoxyphenyl)-3-oxo-3-(piperidin-1-yl)prop-1-en-2-yl)benzamide is used as a subject of study for understanding its reactivity, potential interactions with biological targets, and its overall suitability for drug development. (Z)-N-(1-chloro-1-(4-methoxyphenyl)-3-oxo-3-(piperidin-1-yl)prop-1-en-2-yl)benzamide's structural complexity offers opportunities for optimizing its properties and exploring its potential in creating new therapeutic agents.
Used in Drug Discovery:
(Z)-N-(1-chloro-1-(4-methoxyphenyl)-3-oxo-3-(piperidin-1-yl)prop-1-en-2-yl)benzamide is utilized in drug discovery processes to identify its potential as a lead compound. (Z)-N-(1-chloro-1-(4-methoxyphenyl)-3-oxo-3-(piperidin-1-yl)prop-1-en-2-yl)benzamide's unique structure and functional groups make it an interesting starting point for the development of novel therapeutics, particularly in the search for new treatments for various diseases and conditions.

Upstream product

• 5429-22-1 4-(4-methoxybenzylidene)-2-phenyl-5(4H)-oxazolone 
• 123-11-5 4-methoxy-benzaldehyde 
• 201989-25-5 C₂₂H₂₄N₂O₃ 
• 495-69-2 Hippuric Acid 
• 98-88-4 benzoyl chloride 

Relevant academic research and scientific papers

Synthesis and quantitative structure-activity relationships study for phenylpropenamide derivatives as inhibitors of hepatitis B virus replication

A series of new phenylpropenamide derivatives containing different substituents was synthesized, characterized and evaluated for their anti-hepatitis B virus (HBV) activities. The quantitative structure eactivity relationships (QSAR) of phenylpropenamide compound have been studied. The 2D-QSAR models, based on DFT and multiple linear regression analysis methods, revealed that higher values of total energy (TE) and lower entropy (Sθ) enhanced the anti-HBV activities of the phenylpropenamide molecules. Predictive 3D-QSAR models were established using SYBYL multifit molecular alignment rule. The optimum models were all statistically significant with cross-validated and conventional coefficients, indicating that they were reliable enough for activity prediction.

Phenylpropenamide derivatives: Anti-hepatitis B virus activity of the Z isomer, SAR and the search for novel analogs

Phenylpropenamides have been reported to be a class of non-nucleoside inhibitors of the hepatitis B virus (HBV). This class of compounds was explored with the objective of developing potent anti-HBV agents, with a novel mechanism of action, that could be combined with nucleos(t)ide analogs currently used to treat HBV infection. To accomplish this objective a series of substituted arylpropenamide derivatives were prepared and the E and Z geometrical isomers were separated. The structural identity of each of the E and Z isomers was determined by single crystal X-ray crystallography. Contrary to previous reports, the activity of this class of molecules resides in the Z isomer. Further structure-activity relationship studies around the active Z isomer identified compounds that displayed potent antiviral activity against HBV with EC90 value of approximately 0.5 μM in vitro. Attempts to develop ring constrained analogs did not lead to active HBV inhibitors.